Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst

A Needham analyst predicts that Lucid Diagnostics (NASDAQ: LUCD) will see a surge in testing volumes with expected Medicare reimbursement approval. Latest Ratings for LUCD Date Firm Action From To Dec 2021 Ascendiant Capital Initiates Coverage On Buy Dec 2021 Needham Maintains Buy Nov 2021 BTIG Initiates Coverage On Buy View More Analyst Ratings for…

Read More